Synergy, Inc., a biotechnology company, developed and patented a diagnostic product called Revertex. Synergy purchased some research equipment to be used exclusively for Revertex and subsequent research projects. Synergy defeated a legal challenge to its Revertex patent, and began production and marketing of the product. Corporate headquarters' costs were allocated to Synergy's research division as a percentage of the division's salaries. Your assignment: Take a position on the appropriate accounting for R&D costs (capitalization, expensing, or that companies should be able to choose either capitalization or expensing). Provide a list of arguments in support of your view. Do not let the method required by the FASB influence your decision. Your arguments should be based on your interpretation of the merits for the choices available.